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Abstract Small GTPases are molecular switches that control 
signaling pathways critical for diverse cellular functions. Recent 
evidence indicates that multiple effector molecules can be 
activated by small GTPases. As a result, complex biological 
processes such as cell proliferation and apoptosis are turned on. 
Thus, rather than a single linear pathway from the membrane to 
the nucleus, the integration of complementary signals is required 
for these events to occur. In fact, the coordinated activation of 
small GTPases may constitute some of the critical modulators of 
those signals triggering either proliferation or cell death. In 
addition to the activation of specific kinases cascades, phospho-
lipid-derived messengers are candidates to compose some of the 
most critical elements associated to regulation of signaling 
cascades capable of discerning among life and death. Both 
proliferation and apoptosis needs competence and progression 
signals. Phospholipase D and sphingomyelinase may be im-
portant players in this decision-maker step. 
© 1997 Federation of European Biochemical Societies. 
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1. Ras superfamily of proteins 
The family of ras genes include more than 50 members 
grouped in at least three major subfamilies or branches ac-
cording to their primary structures [1]. They all code for pro-
teins with a molecular mass of 20-25 kDa and homologies 
ranging from 30 to 60% that bind and hydrolyze GTP allow-
ing them to modulate the activity of a great diversity of ef-
fector molecules. Thus, when associated to GDP, these 
GTPases stay as resting, non-active complexes but become 
activated when bound GDP is exchanged for GTP by their 
interaction with specific exchange factors [1,2]. The three ma-
jor branches comprise the Rab subfamily, involved in the 
regulation of secretion and vesicular trafficking, the Ras sub-
family, involved in the regulation of cell growth and differ-
entiation, and the Rho subfamily, involved in the regulation 
of cell growth and apoptosis. In addition, activation of Ras 
and Rho proteins affect cell morphology. Finally, an impor-
tant member of this superfamily is the family of ADP-ribosyl-
ation factors (ARF) involved in the activation of cholera 
toxin, regulation of phospholipase D (PLD) and membrane 
traffic [3]. 
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2. Phospholipid metabolism in cell signaling: involvement in cell 
proliferation 
Membrane phospholipids are essential structural compo-
nents of eukaryotic cells, but also play an important role in 
the control of diverse cellular responses. One of the best char-
acterized examples is phosphatidyl-inositol,l-4 bisphosphate 
(PIP2). Hydrolysis of this lipid by a phosphoinositide (PI)-
specific phospholipase C (PI-PLC) results in the generation 
of diacylglycerol (DAG), and inositol-l,4,5-triphosphate 
(IP3). This pathway is activated by a large variety of mito-
genic factors by either tyrosine phosphorylation or heterotri-
meric GTPases in the regulation of PI-PLC [4]. Generation of 
DAG and IPs induces activation of PKC [5]. However, this 
pathway is dispensable for mitogenic stimulation by growth 
factors since normal mitogenicity is observed with mutated 
receptors unable to activate PI-PLC [6,7]. 
Mitogenic stimulation of RTKs induces a bimodal produc-
tion of DAG. The first wave occurs immediately after stim-
ulation and is maintained for a few minutes. The second wave 
takes place at later times of stimulation and is much more 
sustained in time. The early DAG peak is associated to PI 
hydrolysis by specific phospholipases, while no detectable re-
lease of IP3 is associated to the late DAG peak [4,5]. These 
results suggested the existence of a DAG source different from 
that of PI hydrolysis that was identified as phosphatidylcho-
line (PC) [8]. This hypothesis was supported further by the 
evidence that several growth factors induce PC hydrolysis in a 
more sustained manner that PI hydrolysis, coincident with the 
second wave of DAG. The finding that oncogenic ra^-p21s 
induced the constitutive increased generation of phosphoryl-
choline (PCho) and DAG, provided the evidence for a con-
stitutive increase in the hydrolysis of PC [9]. 
PCho is produced in fibroblasts as a result of treatment 
with mitogenic factors at both early (1 min) and late times 
(4-12 h) of induction, as a consequence of the consecutive 
activation of PLD and choline kinase [10,11]. Phosphorylcho-
line (PCho) has been proposed as an essential lipid metabolite 
involved in the regulation of DNA synthesis in murine fibro-
blasts. This hypothesis is based on the finding that inhibition 
of PCho production by hemicholinium-3 (HC-3), a choline 
kinase inhibitor, completely eliminates DNA-synthesis in cells 
stimulated with growth factors including PDGF, bFGF and 
EGF but not by serum, implying a non-toxic effect [10,11]. 
Furthermore, the inhibitory effect is cell-cycle dependent [11] 
and can be reverted by addition of insulin [10]. Consistent 
with these results, novel compounds derived from HC-3 
with up to 2000-fold higher inhibitory activity towards 
ChoK, show also a similar effect on DNA synthesis stimula-
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tion by growth factors [Hernandez-Alcoceba et al., submit-
ted], providing further support to the role of PCho in the 
regulation of the mitogenic response. Finally, tumor samples 
are frequently associated with an increase in PCho compared 
to the normal cells [12,13], a strong support to the hypoth-
esis of an important role for this metabolite in cell growth 
control. 
Other lipid pathways have been implicated in the regulation 
of cell growth. PLD is activated by receptor Tyr kinases 
(RTK) or PKC activators [8]. Hydrolysis of PC by PLD gen-
erates phosphatidic acid (PA) and choline, and represents also 
a common response to a large variety of mitogens. PA is a 
weak mitogen for fibroblasts, while Lyso-PA (LPA), which 
results from phospholipase A2 action on PA, shows a more 
potent mitogenic activity [14,15]. Choline itself has no mito-
genic activity, but it is required for the biosynthesis of PC [16]. 
A role in the regulation of cell growth has been reported for 
sphingosine-1-phosphate [17] or sphingosylphosphorylcholine 
[18]. These metabolites are related to IP3-independent Ca2+ 
mobilization, and PLD activation [19]. 
3. Regulation of PLD by small GTPases of the Ras 
superfamily 
Generation of PCho and DAG in both serum-treated cells 
and in raw-transformed cells requires a two-hits mechanism 
[20]. When choline kinase (ChoK) was inhibited by hemicho-
linium-3 (HC-3), PCho levels did not increase after serum 
stimulation, while DAG increased as in HC-3 untreated cells, 
an indication that PCho production was sensitive to ChoK 
blockage. By contrast, when cells were stimulated by serum in 
the presence of propranolol, DAG levels were those of non-
stimulated cells, indicating that DAG production was sensi-
tive to PA hydrolase. Moreover, while no significant activa-
tion of PC-PLC was detected, a clear activation of a PC-PLD 
was observed after serum addition [20]. Similar results were 
observed in the basal, constitutively increased levels of DAG 
and PCho found in ras-transformed NIH 3T3 cells [20-23]. 
Thus, by using HC-3 and propranolol, generation of DAG 
and PCho in normal cells stimulated by serum and in raw-
transformed cells can be uncoupled. These results are similar 
to those found in fibroblast cells transformed by the src or raf 
oncogenes [23,24]. Activation of PLD by Ras is independent 
of PKC, but synergizes with phorbol esters [25]. In addition, 
ras transformation uncouples PLD activation by growth fac-
tors through specific interference with the activation of the PI-
PLCy pathway [25]. These results suggest the existence of both 
forward and feed-back mechanisms in the regulation of cell 
responses by phospholipid metabolites. 
By contrast to the results obtained in the raw-transformed 
cells, in normal cells stimulated by serum, PLD activation 
follows a transient kinetics with a maximal activity detected 
at 30 min of stimulation, and a residual activation of around 
20% increase from 1 to at least 12 h of stimulation [26]. As a 
consequence, PA levels rise in NIH 3T3 cells stimulated by 
serum and decreases to almost basal levels after 60 min. How-
ever, at late times of serum stimulation, both choline release, 
and PCho and DAG levels are elevated, like in raw-trans-
formed cells. The nature of this increase is still not clear, 
but a residual PLD activation could explain all these events 
as previously suggested [26]. DAG does participate in the 
activation of the conventional and novel PKCs with impor-
tant consequences regarding the progression to cell prolifera-
tion or apoptosis [[5]; see next paragraph]. 
The comparative study from both Xenopus oocytes and 
mammalian fibroblasts indicates that raw-p21 proteins activate 
a PLD enzyme in both systems, generating PA, DAG and 
PCho as active metabolites [10,11,27,28]. However, the bio-
logical function of each one of these metabolites depends on 
the specific cellular system. In fibroblasts, in addition to the 
increased PLD activity, other enzymes such as choline kinase 
and PA-phosphohydrolase may be also required. However, in 
X. laevis, PA seems to be sufficient to carry out the biological 
function through activation of the Ser/Thr kinase cascade 
[27,28]. These results could also be expanded to other cellular 
systems with different biological responses. 
Other small GTPases and oncogenes are also capable of 
activating PLD. Basal levels of src- [24] and rAo-transformed 
cells [29] have increased PLD activity with elevated PA, Cho 
and PCho metabolites. These results are consistent with those 
reported using cell-free systems, where both Rho and ARF-1 
proteins have been shown to activate PLD [30,31]. Finally, it 
has been reported recently that activation of PLD induced by 
src is mediated by a Ras- and Ral-dependent mechanism [32]. 
Regulation of PLD may be complex since it has been dem-
onstrated that activation of PLD by growth factors follows a 
two-ways mechanism. Both a PI-PLC/DAG/PKC-dependent 
pathway, triggered by growth factors, and a Ras-dependent, 
PKC-independent pathway has been demonstrated [25]. Fur-
thermore, while activation by growth factors and phorbol 
esters show a cooperative pattern which results in an additive 
mechanism, transformation by the ras, sis, src and met onco-
genes results in a synergistic activation of PLD by phorbol 
esters treatment [25]. In addition, transformation by the ras, 
src and met oncogenes results in a complete abrogation of the 
PI-PLC-dependent activation of PLD by growth factors [25]. 
However, transformation by other oncogenes such as fgr, fins 
or overexpression of TGFoc, does not affect PLD activation 
by phorbol esters or growth factors, an indication that each 
oncogene may or may not use the PLD pathway in a defined 
and specific manner dependent on endogenous signaling path-
ways. PLD has potent mitogenic activity by itself [15,20]. 
Thus, significant differences in PLD regulation by different 
oncogenes may contribute to the unrestricted cell growth in 
transformed cells. 
4. Phospholipids and apoptosis 
There are at least two important types of lipid derivatives 
which may affect regulation of apoptosis: ceramides and 
PI3K-derived metabolites PI(3,4)P3 and PI(3,4,5)P3. Ceram-
ides are produced as a consequence of activation of sphingo-
myelinase, a phospholipase C specific for sphingomyeline, 
while PI(3,4)P3 and PI(3,4,5)P3 results from the activation 
of PI3K. Ceramides function as inhibitors of cell growth by 
a mechanism that may involve a protein phosphatase of the 
PP2A type, and at least two types of Ser/Thr protein kinases 
[33,34]. Ceramides have been described as natural PKC inhib-
itors, generated as a result of treatment with several agents 
such as TNFrx, ylNF, IL-1 and others. As a further support 
for the role of ceramides in the regulation of cell growth, it 
has been recently found that ceramides induce apoptosis and 
that this effect can be reverted by activation of PKC with 
phorbol esters. Ceramides have been shown to induce the 
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activation of both the Rafl kinase pathway in HL60 [35] as 
well as the JNK/SAPK pathway in U937 cells [36]. Ceramides 
can be converted into sphingosine-1-phosphate (SPP) via 
sphingosine, and these two metabolites, ceramides and SPP, 
have been suggested to carry out opposite effects on cell 
growth and apoptosis [37]. A recent report suggest that SPP 
and PCho synergize for mitogenic stimulation [38], suggesting 
a cross-talk connection of these two metabolites. 
5. Small GTPases in apoptosis 
Strong evidence that Ras-related proteins may be involved 
in the regulation of apoptosis mostly comes from Ras and 
Rho proteins. Both proteins have been shown to behave as 
oncogenes in murine fibroblasts [39-41]. Although the Ras 
proteins are more potent than Rho proteins, ras-dependent 
transformation requires Rho function [40,41]. In addition, 
Ras is capable of inhibiting apoptosis in murine fibroblasts 
and epithelial cells by activating PI3K [42-44]. The products 
of the PI3K can trigger survival signals through activation of 
the serine/threonine kinase PKB/Akt [42-44], but other path-
ways cannot be ruled out. Activation of PI3K is achieved by 
growth factors such as PDGF or IGF-I, and oncogenic Ras 
proteins. Rho proteins (Aplysia Rho, and the human Rho A, 
Rho C, and Racl), on the other hand, enhances apoptosis in 
murine fibroblasts and the human K562 erythroleukemia cells 
after serum deprivation, by a p53-independent mechanism 
[[45]; Esteve et al., submitted]. Finally, apoptosis by Rho 
proteins is related to the generation of ceramides [29] and 
can be blocked by Bcl2 expression both in vitro and in vivo 
[Esteve et a l , submitted]. 
It has been recently demonstrated that apoptosis induced 
by Rho proteins requires complementary signals (Fig. 1), sim-
ilar to the requirement for competence and progression signals 
in cell proliferation [[29,45]; Esteve et al., submitted]. While 
the progression signal is associated to ceramides production 
[29], the competence signal has to be yet identified. However, 
some hints are already available that can help identifying this 
partner. Rho proteins can induce the activation of multiple 
signaling pathways, including lipid enzymes such as PLD [29-
31], PI3K [46] and PI5K [47], several diverse serine/threonine 
kinases [48-54] and myosin phosphatase [54]. In addition, 
Rho proteins can induce the activation of transcription fac-
tors such as Jun [55,56], SRF [57] and N F - K B [58]. Among all 
these effectors and activated pathways, it is critical to establish 
which ones are relevant for proliferation and apoptosis. Evi-
dence for a dual role of JNK/SAPK and N F - K B in cell trans-
formation and apoptosis has been reported [59], as for Rho 
[29,39-41,45] suggesting that they could be involved in either 
process induced by Rho. 
Therefore, Ras and Rho proteins have the ability to acti-
vate transforming signals as well as signals that regulate apop-
tosis, either positively or negatively. The final outcome de-
pends upon the environmental conditions and cell type 
[29,39-45]. A critical component of the signaling pathways 
discerning between proliferation and apoptosis may be the 
Fig. 1. Requirement of complementary signals for the induction of apoptosis. At least two complementary signals are required for the induction 
of apoptosis by Rho proteins in murine fibroblasts. While the progression signal has been identified as ceramides, the initiation signal could be 
any of the known signaling pathways activated by Rho, such as the JNK/SAPK kinase or the NF-KB transcription factors, two molecules in-
volved in apoptosis in several cell systems. 
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Fig. 2. Differential effects of Ras and Rho activation. Activation of specific signaling pathways involving lipid metabolism and diverse kinases 
would end in the generation of either cell growth or apoptosis. The final cellular response depends upon the integration of the complementary 
pathways activated. See text for details. 
lipid component activated in each case. A major difference 
among these two proteins is that constitutively activated 
Ras protein can activate PLD and PI3K but not ceramides 
production, even in the absence of survival signals such as 
serum. These signals can turn on a survival response. Rho 
proteins activate PLD and Pi-related kinases, but after serum 
removal they can activate also sphingomyelinase, resulting in 
the generation of ceramides (Fig. 2). Other components of 
both Ras- and Rho-dependent signaling such as the Raf/ 
MAPK and the JNK/SAPK kinases and specific transcription 
factors may play a role in the integration response. 
6. Perspectives and future 
The Ras superfamily of proteins comprises small, but func-
tionally complex, proteins which serves as critical switches for 
the regulation of multiple cellular functions. Both the Ras and 
Rho branches have been shown to be critical for regulation of 
cell proliferation and apoptosis. The mechanism of activation/ 
inactivation of small GTPases has been elucidated concisely, 
and some of the specific molecular species involved identified, 
so we can now have a reasonably good understanding on their 
importance for diverse cell responses. However, a complete 
picture of the intricate and complex interactive networks for 
Ras and Rho proteins is still poorly understood. Thus, the 
finding that Ras proteins physically interact with at least Raf-
1 kinase, PI3K and Ral-GDS activating all these pathways, 
may not be sufficient to explain all their known functions. 
Similarly, Rho proteins have shown to be even more complex 
than Ras, with a larger number of effector molecules identified 
so far. On top of that all, Ras-mediated transformation re-
quires Rho functions, and both Ras and Rho play a dual role 
in transformation and apoptosis. 
All the results discussed above suggest that phospholipid 
metabolites are important elements in the regulation of signal-
ing cascades activated by GTPases of the Ras and Rho fam-
ilies. They function either in combination with complementary 
signals that activate specific kinases/phosphatases cascades 
ending in the upregulation of diverse transcription factors 
(AP-1, Fos, Jun, N F - K B , etc), or as an integral part of the 
kinases/phosphatases pathway. Simultaneous activation of 
both 'proliferation' as well as 'apoptosis' signals is a frequent 
event. The final result depends on the proper integration of 
signals by the target cell. Thus, understanding of the biochem-
ical pathways activated by each effector for both Ras and Rho 
proteins will be critical for a better knowledge of the biolog-
ical consequences and a more comprehensive consideration of 
the mechanism of regulation of both cell growth and apopto-
sis. 
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